Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial

Paul G. Richardson(Harvard University), Robert J. Soiffer(Dana-Farber Cancer Institute), Joel A. Brochstein(Cohen Children's Medical Center), Alfred P. Gillio(University Medical Center), Eneida R. Nemecek(Oregon Health & Science University), Sally Arai(Stanford Medicine), Joseph H. Antin(Dana-Farber Cancer Institute), Eva C. Guinan(Dana-Farber Cancer Institute), Shin Mineishi(University of Alabama at Birmingham), Massimo Iacobelli(Figli Adottivi e Genitori Naturali), Gideon Steinbach(University of Washington), Stephan A. Grupp(Children's Hospital of Philadelphia), Nancy A. Kernan(Memorial Sloan Kettering Cancer Center), Paul Martin(Duke Medical Center), Maja Miloslavsky(Janssen (United States)), Bijan Nejadnik(Janssen (United States)), Alison L. Hannah(CytomX Therapeutics (United States)), Reggie Duerst(Lurie Children's Hospital), Robin Hume(Jazz Pharmaceuticals (United States)), Rajinder Bajwa(Nationwide Children's Hospital), Amrita Krishnan(City of Hope), Leslie Lehmann(Harvard University)
Transplantation and Cellular Therapy
February 18, 2016
Cited by 1


Related Papers